Bone Fracture Repair by Targeting of Bone Anabolic Agents

Back to all technologies
Download as PDF
2015-LOW-67195
Current research on healing bone fractures either focuses on localized application of a nontargeted bone anabolic agent or a systematic administration of a nontargeted bone anabolic agent that have off-target effects. Both methods lack the desired efficiency and effectivity to treat bone fractures.

Researchers at Purdue University have developed a targeted bone anabolic agent capable of accelerated fracture healing. By using a construct that self-assembles into micelles, the technology targets bone fractures to a greater extent than healthy bone, releases drug under physiological conditions, and accelerates fracture healing. This technology utilizes a nontoxic acidic oligopeptide that increases accumulation of the drug in fractures, reduces the accumulation in healthy tissue, and uses a cleavable linker to extend the release of the drug in the fracture site, resulting in faster fracture healing.

Advantages
-Nontoxic acidic oligopeptide increases accumulation of the drug in fractures and decreases drug accumulation in healthy tissue.

Potential Applications:
-Medical/Health
-Orthopedics
-Pharmaceuticals
Jan 31, 2019
CON-Patent
United States
10,744,203
Aug 18, 2020

Nov 29, 2017
NATL-Patent
United States
10,279,044
May 7, 2019

Jul 13, 2020
CON-Gov. Funding
United States
(None)
(None)

May 29, 2016
PCT-Patent
WO
(None)
(None)

May 29, 2015
Provisional-Patent
United States
(None)
(None)

(None)
NATL-Patent
Japan
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org